Jefferies HJ, Tertti R, Wittfooth S, Burton JO, Metsarinne K, Pettersson K, McIntyre CW

Smyth A, Dehghan M, O'Donnell M, Anderson C, Teo K, Gao P, Sleight P2, Dagenais G, Probstfield JL, Mente A, Yusuf S; On behalf of the ONTARGET and TRANSCEND Investigators

Panduru NM, Saraheimo M, Forsblom C, Thorn LM, Gordin D, Wadén J, Tolonen N, Bierhaus A, Humpert PM, Groop PH; FinnDiane Study Group

Dunkler D, Kohl M, Heinze G, Teo KK, Rosengren A, Pogue J, Gao P, Gerstein H, Yusuf S, Oberbauer R, Mann JF; for the ONTARGET Investigators

Metsarinne K, Broijersen A, Kantola I, Niskanen L, Rissanen A, Appelroth T, Pontynen N, Poussa T, Koivisto V, Virkamaki A; for the STONE (STages of NEphropathy in type 2 diabetes) study investigators

Todd JN, Dahlström EH, Salem RM, Sandholm N, Forsblom C; the FinnDiane Study Group, McKnight AJ, Maxwell AP, Brennan E, Sadlier D, Godson C, Groop PH, Hirschhorn JN, Florez JC

Kaj Metsärinne, Ilkka Tikkanen

Panduru NM, Sandholm N, Forsblom C, Saraheimo M, Dahlström EH, Thorn LM, Gordin D, Tolonen N, Wadén J, Harjutsalo V, Bierhaus A, Humpert PM, Groop PH; on behalf of the FinnDiane Study Group

Wadén J, Tikkanen HK, Forsblom C, Harjutsalo V, Thorn LM, Saraheimo M, Tolonen N, Rosengård-Bärlund M, Gordin D, Tikkanen HO, Groop PH; on behalf of the FinnDiane Study Group

Simonsen Jr, Harjutsalo V, Järvinen A, Kirveskari J, Forsblom C, Groop PH, Lehto M; on behalf of the FinnDiane Study Group